Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

25.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

170
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
170
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

405
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
405
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
What is Genetic Engineering?00:49

What is Genetic Engineering?

73.0K
Overview
73.0K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.7K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopamine replacement therapy modulates DDC, prolactin and AOC3 levels in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Dysregulation of sphingolipid-metabolizing enzymes in Friedreich's ataxia: <i>In vitro</i> and <i>in vivo</i> insights into therapeutic targeting.

iScience·2026
Same author

Data-Driven Electrochemistry Reveals the Impact of Hydrophobicity on Aptamer Cross-Reactivity.

ACS measurement science au·2026
Same author

Reactive astrocytes mediate toxicity in iPSC derived dopaminergic neurons.

NPJ Parkinson's disease·2026
Same author

Subcellular localization of enzymes involved in the biosynthesis of digoxin in <i>Digitalis lanata</i>.

Frontiers in plant science·2026
Same author

Mutant TDP-43 drives impairments in axonal transport and glycolysis in a mouse stem-cell-derived motor neuron model of amyotrophic lateral sclerosis (ALS).

Cell death & disease·2026

Related Experiment Video

Updated: May 21, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.9K

Recent developments in gene therapy for Parkinson's disease.

Sandor Szunyogh1, Emily Carroll1, Richard Wade-Martins1

  • 1Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford OX1 3QU, UK.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|March 23, 2025
PubMed
Summary

Gene therapy offers new hope for Parkinson's disease (PD) by targeting its root causes. Researchers are exploring various strategies to restore dopamine, enhance neuronal survival, and reduce toxic proteins for effective PD treatments.

Keywords:
AAVHSV-1Parkinson’s diseasedopamine neuronsgene therapygrowth factor deliverylentivirusneuromodulation

More Related Videos

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.2K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

5.8K

Related Experiment Videos

Last Updated: May 21, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.9K
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.2K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

5.8K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder with no current cure.
  • Gene therapy presents a promising avenue for developing novel PD treatments.

Purpose of the Study:

  • To review current gene therapy strategies for Parkinson's disease.
  • To explore methods targeting dopamine system restoration, GABAergic signaling, neurotrophic support, mitochondrial function, lysosomal activity, and alpha-synuclein reduction.

Main Methods:

  • Review of existing gene therapy approaches for PD.
  • Analysis of strategies involving gene delivery via viral vectors.
  • Discussion of methods to control gene expression and minimize immune responses.

Main Results:

  • Multiple gene therapy strategies are under development for PD.
  • Approaches include dopamine biosynthesis enhancement, GAD delivery for GABA production, neurotrophic factor introduction, gene correction for mitochondrial dysfunction, GBA1 delivery for lysosomal function, and SNCA silencing.
  • Challenges include vector optimization, controlled gene expression, immune response mitigation, and delivery capacity.

Conclusions:

  • Gene therapy holds significant potential for treating Parkinson's disease.
  • Overcoming challenges in delivery, expression, and immunogenicity is crucial for clinical success.
  • Combinatorial strategies and advanced viral systems may offer future therapeutic advancements.